Common Contracts
2 similar Research and Development Agreement contracts
Agreement Between a Chromogenic Modified Nijmegen- Bethesda Assay and a Qualitative ELISA test in Detection of Factor VIII Inhibitors in Plasma from Persons with Hemophilia A (PwHA)Research and Development Agreement • February 13th, 2018
• An inhibitor response via antibody development to Factor VIII (FVIII) replacement therapies is the most significant complication of hemophilia A treatment today.
Agreement Between a Chromogenic Modified Nijmegen- Bethesda Assay and a Qualitative ELISA test in Detection of Factor VIII Inhibitors in Plasma from Persons with Hemophilia A (PwHA)Research and Development Agreement • February 13th, 2018
• An inhibitor response via antibody development to Factor VIII (FVIII) replacement therapies is the most significant complication of hemophilia A treatment today.